Altered gene expression in Opisthorchis viverrini-associated cholangiocarcinoma in hamster model

Molecular Carcinogenesis

Volumn 45, Issue 5, 2006, Pages 279-287

  Loilome, Watcharin ^a,b   Yongvanit, Puangrat ^a   Wongkham, Chaisiri ^a   Tepsiri, Nisana ^a   Sripa, Banchob ^a   Sithithaworn, Paiboon ^a   Hanai, Shuji ^b   Miwa, Masanao ^b,c  

^a KHON KAEN UNIVERSITY   (Thailand)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c NAGAHAMA INSTITUTE OF BIO SCIENCE AND TECHNOLOGY   (Japan)

Author keywords

Cholangiocarcinoma; Fluorescence differential display PCR; Protein kinase A regulatory subunit 1

Indexed keywords

BETA ACTIN; BETA TUBULIN; BINDING PROTEIN; COLLAGEN TYPE 6; CYCLIC AMP DEPENDENT PROTEIN KINASE; DIMETHYLNITROSAMINE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; LIM PROTEIN; MARCKS PROTEIN; OXYSTEROL BINDING PROTEIN; REGULATOR PROTEIN; UBIQUITIN CONJUGATING ENZYME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT CARCINOMA; CARCINOGENESIS; CONTROLLED STUDY; DIFFERENTIAL DISPLAY; FLUORESCENCE; GALLBLADDER EPITHELIUM; GENE FUNCTION; GENE OVEREXPRESSION; HISTOPATHOLOGY; LIPID METABOLISM; LIVER; MALIGNANT TRANSFORMATION; MOLECULAR CLONING; NONHUMAN; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; OPISTHORCHIS VIVERRINI; PRIORITY JOURNAL; PROTEIN DEGRADATION; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SYRIAN HAMSTER; THAILAND;

ANIMALS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BLOTTING, NORTHERN; CHOLANGIOCARCINOMA; CRICETINAE; DISEASE MODELS, ANIMAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; MESOCRICETUS; NEOPLASM PROTEINS; NITROSAMINES; OPISTHORCHIASIS; OPISTHORCHIS;

CRICETINAE; FASCIOLA HEPATICA; OPISTHORCHIS VIVERRINI;

EID: 33646743628     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20094     Document Type: Article

References (48)

1. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Schistosomes, liver flukes and Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum 1994;61:1-241.
2. Haswell-Elkins MR, Mairiang E, Mairiang P, et al. Cross-sectional study of Opisthorchis viverrini infection and cholangiocarcinoma in communities within a high-risk area in northeast Thailand. Int J Cancer 1994;59:505-509.
3. Pinlaor S, Yongvanit P, Hiraku Y, et al. 8-nitroguanine formation in the liver of hamsters infected with Opisthorchis viverrini. Biochem Biophys Res Commun 2003;309:567-571.
4. Pinlaor S, Ma N, Hiraku Y, et al. Repeated infection with Opisthorchis viverrini induces accumulation of 8-nitroguanine and 8-oxo-7,8-dihydro-2′- deoxyguanine in the bile duct of hamsters via inducible nitric oxide synthase. Carcinogenesis 2004;25:1535-1542.
5. Harnois DM, Que FG, Celli A, LaRusso NF, Gores GJ. Bcl-2 is overexpressed and alters the threshold for apoptosis in a cholangiocarcinoma cell line. Hepatology 1997;26:884-890.
6. Kang YK, Kim WH, Lee HW, Lee HK, Kim YI. Mutation of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma. Lab Invest 1999;79:477-483.
7. Furubo S, Harada K, Shimonishi T, Katayanagi K, Tsui W, Nakanuma Y. Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma. Histopathology 1999;35:230-240.
8. Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 2000;60:184-190.
9. Ito T, Kito K, Adati N, Mitsui Y, Hagiwara H, Sakaki Y. Fluorescent differential display: Arbitrarily primed RT-PCR fingerprinting on an automated DNA sequencer. FEBS Lett 1994;351:231-236.
10. Iida R, Yasuda T, Aoyama M, Tsubota E, Matsuki T, Kishi K. Age-related changes of gene expression in mouse kidney: Fluorescence differential display-PCR analyses. Mech Ageing Dev 2000;113:135-144.
11. Thamavit W, Bhamarapravati N, Sahaphong S, Vajrasthira S, Angsubhakorn S. Effects of dimethylnitrosamine on induction of cholangiocarcinoma in Opisthorchis viverrini-infected Syrian golden hamsters. Cancer Res 1978;38:4634-4639.
12. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
13. Sharma R, Samantaray S, Shukla NK, Ralhan R. Transcriptional gene expression profile of human esophageal squamous cell carcinoma. Genomics 2003;81:481-488.
14. Church GM, Gilbert W. Genomic sequencing. Proc Natl Acad Sci USA 1984;81:1991-1995.
15. Cho-Chung YS, Pepe S, Clair T, Budillon A, Nesterova M. cAMP-dependent protein kinase: Role in normal and malignant growth. Crit Rev Oncol Hematol 1995;21:33-61.
16. Handschin JC, Eppenberger U. Altered cellular ratio of type I and type II cyclic AMP-dependent protein kinase in human mammary tumors. FEBS Lett 1979;106:301-304.
17. Miller WR, Hulme MJ, Bartlett JM, MacCallum J, Dixon JM. Changes in messenger RNA expression of protein kinase A regulatory subunit ialpha in breast cancer patients treated with tamoxifen. Clin Cancer Res 1997;3:2399-2404.
18. Simpson BJ, Ramage AD, Hulme MJ, et al. Cyclic adenosine 3′,5′-monophosphate-binding proteins in human ovarian cancer: Correlations with clinicopathological features. Clin Cancer Res 1996;2:201-206.
19. McDaid HM, Cairns MT, Atkinson RJ, et al. Increased expression of the RIalpha subunit of the cAMP-dependent protein kinase A is associated with advanced stage ovarian cancer. Br J Cancer 1999;79:933-939.
20. Young MR, Montpetit M, Lozano Y, et al. Regulation of Lewis lung carcinoma invasion and metastasis by protein kinase A. Int J Cancer 1995;61:104-109.
21. Bold RJ, Alpard S, Ishizuka J, Townsend CM Jr., Thompson JC. Growth-regulatory effect of gastrin on human colon cancer cell lines is determined by protein kinase a isoform content. Regul Pept 1994;53:61-70.
22. Bradbury AW, Carter DC, Miller WR, Cho-Chung YS, Clair T. Protein kinase A (PK-A) regulatory subunit expression in colorectal cancer and related mucosa. Br J Cancer 1994;69:738-742.
23. Gordge PC, Hulme MJ, Clegg RA, Miller WR. Elevation of protein kinase A and protein kinase C activities in malignant as compared with normal human breast tissue. Eur J Cancer 1996;32A:2120-2126.
24. Cho-Chung YS, Nesterova M, Kondrashin A, Noguchi K, Srivastava R, Pepe S. Antisense-protein kinase A: A single-gene-based therapeutic approach. Antisense Nucleic Acid Drug Dev 1997;7:217-223.
25. Wang H, Cai Q, Zeng X, Yu D, Agrawal S, Zhang R. Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration. Proc Natl Acad Sci USA 1999;96:13989-13994.
26. Chen HX, Marshall JL, Ness E, et al. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors. Clin Cancer Res 2000;6:1259-1266.
27. Nesterova M, Cho-Chung YS. Oligonucleotide sequence-specific inhibition of gene expression, tumor growth inhibition, and modulation of cAMP signaling by an RNA-DNA hybrid antisense targeted to protein kinase A RIalpha subunit. Antisense Nucleic Acid Drug Dev 2000;10:423-433.
28. Tortora G, Bianco R, Damiano V, et al. Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production. Clin Cancer Res 2000;6:2506-2512.
29. Cho YS, Cho-Chung YS. Antisense protein kinase A RIalpha acts synergistically with hydroxycamptothecin to inhibit growth and induce apoptosis in human cancer cells: Molecular basis for combinatorial therapy. Clin Cancer Res 2003;9:1171-1178.
30. Wolfman A, Wingrove TG, Blackshear PJ, Macara IG. Down-regulation of protein kinase C and of an endogenous 80-kDa substrate in transformed fibroblasts. J Biol Chem 1987;262:16546-16552.
31. Simek SL, Kligman D, Patel J, Colburn NH. Differential expression of an 80-kDa protein kinase C substrate in preneoplastic and neoplastic mouse JB6 cells. Proc Natl Acad Sci USA 1989;86:7410-7414.
32. Otsuka M, Yang HC. Decreased expression of the myristoylated alanine-rich C kinase substrate in transformed BALB/C 3T3 mouse fibroblasts. Biochem Biophys Res Commun 1991;178:494-500.
33. Joseph CK, Qureshi SA, Wallace DJ, Foster DA. MARCKS protein is transcriptionally down-regulated in v-Src-transformed BALB/c 3T3 cells. J Biol Chem 1992;267:1327-1330.
34. Rose SD, Cook HW, Palmer FB, Ridgway ND, Byers DM. Differential expression of MARCKS and other calmodulin-binding protein kinase C substrates in cultured neuroblastoma and glioma cells. J Neurochem 1994;63:2314-2323.
35. Manenti S, Malecaze F, Darbon JM. The major myristoylated PKC substrate (MARCKS) is involved in cell spreading, tyrosine phosphorylation of paxillin, and focal contact formation. FEBS Lett 1997;419:95-98.
36. Manenti S, Malecaze F, Chap H, Darbon JM. Overexpression of the myristoylated alanine-rich C kinase substrate inhuman choroidal melanoma cells affects cell proliferation. Cancer Res 1998;58:1429-1434.
37. Gardner-Thorpe J, Ito H, Ashley SW, Whang EE. Differential display of expressed genes in pancreatic cancer cells. Biochem Biophys Res Commun 2002;293:391-395.
38. Levi S, Urbano-Ispizua A, Gill R, et al. Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Res 1991;51:3497-3502.
39. Tsuda H, Satarug S, Bhudhisawasdi V, Kihana T, Sugimura T, Hirohashi S. Cholangiocarcinomas in Japanese and Thai patients: Difference in etiology and incidence of point mutation of the c-Ki-ras proto-oncogene. Mol Carcinog 1992;6:266-269.
40. Dawid IB, Toyama R, Taira M. LIM domain proteins. CR Acad Sci III 1995;318:295-306.
41. Retaux S, Bachy I. A short history of LIM domains (1993-2002): From protein interaction to degradation. Mol Neurobiol 2002;26:269-281.
42. Visvader JE, Venter D, Hahm K, et al. The LIM domain gene LMO4 inhibits differentiation of mammary epithelial cells in vitro and is overexpressed in breast cancer. Proc Natl Acad Sci USA 2001;98:14452-14457.
43. Taylor FR, Kandutsch AA. Oxysterol binding protein. Chem Phys Lipids 1985;38:187-194.
44. Smith LL. Review of progress in sterol oxidations: 1987-1995. Lipids 1996;31:453-487.
45. Fournier MV, Guimaraesda Costa F, Paschoal ME, Ronco LV, Carvalho MG, Pardee AB. Identification of a gene encoding a human oxysterol-binding protein-homologue: A potential general molecular marker for blood dissemination of solid tumors. Cancer Res 1999;59:3748-3753.
46. Hartmann-Petersen R, Gordon C. Proteins interacting with the 26S proteasome. Cell Mol Life Sci 2004;61:1589-1595.
47. Okamoto Y, Ozaki T, Miyazaki K, Aoyama M, Miyazaki M, Nakagawara A. UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme. Cancer Res 2003;63:4167-4173.
48. El-Nady GM, Ling R, Harrison TJ. Gene expression in HCV-ssociated hepatocellular carcinoma-upregulation of a gene encoding a protein related to the ubiquitin-conjugating enzyme. Liver Int 2003;23:329-337.